The correlation between QoL improvements and PFS prolongation is probably due to the well-known efficacy of EGFR and ALK TKIs in NSCLC harboring EGFR mutations or ALK rearrangements. The gene discussed is ALK; the disease is non-small cell lung carcinoma.